Back to News
May 14, 2026 4:02 PM

AstraZeneca's Imfinzi Combo Shows Survival Benefit In Pivotal Bladder Cancer Study

AstraZeneca PLC (NASDAQ:AZN) on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with Imfinzi (durvalumab) and neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy.

The study compared the regimen against standard treatment involving radical cystectomy, with or without approved adjuvant therapy.

The European drug giant said the combination delivered statistically significant and clinically meaningful benefits in both key endpoints.

Read Also:

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers

Imfinzi-Imjudo Combination Shows Mixed Results

A treatment arm evaluating perioperative Imfinzi plus Imjudo (tremelimumab) alongside neoadjuvant enfortumab vedotin also demonstrated a ...